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Summsry 
The CDS0 (B7-1) molecule is a 45-60-kD member of the immunoglobulin superfamily that 
is expressed on a variety of cell types of haematopoietic  origin.  CD80 can provide a critical 
costimulatory signal to T cells by interacting with the T cell surface molecule CD28.  CDS0 
also binds to the CD28-related molecule CTLA4, which is expressed  on activated T cells. Recently, 
additional ligands of CD28 and CTLA4 have  been described in mice and humans. One of them, 
CD86 (B-70 or B7-2) was characterized at the molecular level. Although similar in predicted 
structure to CDS0, it is distantly related in amino acid sequence. In this study, human CD80 
mutants were generated and tested for their ability to maintain the interaction with CD28 leading 
to adhesion and enhanced IL-2 production. Two hydrophobic residues in the V-like domain of 
CDS0 were identified as critical for binding to CD28 and are also important for the interaction 
with CTLA4. These residues are adjacent to the epitope of the BB1 antibody,  which inhibits 
CD28-CD80 interactions. One of these residues, Y87, is conserved in all CD80 and CD86 cloned 
from various species. These results begin to unravel the structural  requirements for binding to 
CD28 and CTLA4. 
D 
uring the onset of an immune response, T cells require 
two distinct signals for efficient activation.  The first 
signal is antigen-specific and is delivered through the TCR 
upon engagement with the antigenic peptide-MHC com- 
plex while the second signal is mediated by the interaction 
of the T cell surface molecule CD28 with ligands expressed 
on APC (1,  2). Its interaction with CD80 (B7-1) leads to 
an increase in cytokine production and T cell proliferation 
(3). Evidences on the role of CD80/CD28  interaction in 
antigen-specific responses have accumulated in the recent past 
(for review see references 4 and 5). This interaction is critical 
since absence of costimulatory molecules on the surface of 
APCs leads to the induction in T cells of a state of anergy 
(reviewed in references 4 and 5).  CD80,  as expected for a 
costimulatory molecule, is expressed on different cell types 
involved in antigen presentation (4). CD80 also has the ca- 
pacity to interact  with CTLA4 (6), a CD28-related  mole- 
cule expressed primarily after T cell activation (7). This in- 
teraction occurs with a 20-fold higher affinity compared to 
CDS0-CD28 interactions, as demonstrated through the use 
of a soluble form of this molecule consisting of the extracel- 
lular domain of CTLA4 fused to the Fc domain of IgG1 (6). 
Structurally,  human CD80  (huCD80) 1 is a 262-residue 
type I transmembrane glycoprotein of  the Ig superfamily  (IgSF) 
(8). CD80 is predicted  to be present at  the cell surface as 
a highly glycosylated single chain molecule with an extracel- 
lular  region consisting  of two Ig-like  domains:  an  NH2- 
terminal V-like domain followed by a C-like domain. Mu- 
rine CD80 (muCDS0) shares 44% identity with its human 
counterpart and recognizes huCD28 as shown by the ability 
of murine cells expressing  CD80  to  costimulate human 
CD4 + T cells (9). Recently, a molecule distantly related to 
CDS0, namely B70 or B7-2, now identified as the CD86 
differentiation antigen (10), was shown in both humans and 
mice to bind CTLA4Ig and to provide costimulatory signals 
through CD28 (11-13). Like CDS0, it is an IgSF member 
with a single V-like and a single C-like extracellular domain, 
but human CD80 and B70 (B7-2) only show 24 and 30% 
amino acid identity in those two domains,  respectively. 
1 Abbreviations used in this paper: CAM, calcein-AM; hu, human;  IgSF, 
immunoglobulin superfamily;  mu, murine. 
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and multiple substitutions were introduced into predicted ex- 
posed sites in the V- and C-like domains with particular em- 
phasis on residues that are conserved between muCD80 and 
huCD80.  The possible role of carbohydrates in this interac- 
tion was also investigated by mutations at conserved poten- 
tial N-linked glycosylation sites. These mutants were assessed 
for  their  effects  on  CD28-mediated  adhesion  to  CD80- 
transfected L cells and on stimulation of IL-2 production by 
CD28 +  T  cells.  Our  results  show  that  two  hydrophobic 
residues at the base of a distal loop in the V domain of CD80 
are critical for the interaction with both CD28 and CTLA4. 
Materials and Methods 
Antibodies.  The anti-human CD80 mAbs L307 (IgG1)  (14), 
2D10 (IgG1), and BB1 (IgM) (15) were kindly provided by Dr. 
L.L. Lanier (DNAX Research Institute, Palo Alto, CA), Dr. D. 
Olive (Institut Paoli Calmette, MarseiLle, France), and Dr. M. Trem- 
blay (CHUL,  Quebec,  Canada),  respectively.  The anti-human 
CD80 mAbl04 (16) was purchased from AMAC (Westbrook, MA). 
The anti-murine CD80 (B7-1) mAb 16-10A1 (17) was a gift from 
Dr. H. Reiser (Dana Farber Cancer Institute, Boston, MA). The 
anti-human CD28 L293 was purchased from Becton Dickinson 
& Co. (Mountain View,  CA). 
Cell Culture and Transfection.  L cells were grown in DMEM 
plus 4 mM dextrose (Sigma Chemical Co., St. Louis, MO), essen- 
tial and nonessential amino acids, 1 mM sodium pyruvate. The Raji 
B cell line, Jurkat T cell line. as well as the Ib2-dependent T cell 
line CTLL-2, with the addition of 10 U/ml rib2 (Cetus Corp., 
Emeryville, CA), were maintained in RPMI 1640. All culture media 
were supplemented with 10% FCS,  2 raM t-glutamine,  10/~M 
2-ME (Sigma Chemical Co.), and 20/~g/ml gentamicin (all from 
GIBCO BRL, Bethesda, MID, unless otherwise stated). L cells were 
cotransfected with 10/~g of wild-type or mutated huCD80 cDNA 
and 1/~g of pSVneo plasmid carrying the neomycin resistance gene 
using the calcium phosphate coprecipitation technique (18). Stable 
transfectants were selected in 2 mg/ml of (3418 (GIBCO BRL). 
Homogeneous  populations  of  wild-type  or  mutated  CD80- 
transfected cells expressing comparable levels of the different forms 
of CD80 were obtained by aseptic cell sorting on a FACStar |  Plus 
(Becton Dickinson). 
Flow Cytometry Analysis.  Transfected  cell  populations  were 
stained with the routine anti-huCD80 mAbs L307, 2D10, mAbl04, 
and  BB1.  FITC-conjugated  goat  antimurine  IgG  or  FITC- 
conjugated goat antimurine IgM were used as secondary antibodies. 
In negative controls, the primary antibody was omitted. Cells were 
analyzed by flow cytometry on a FACScan  |  (Becton Dickinson). 
Live cells were gated by light scatter. A minimum of 10,000 events 
was accumulated for each histogram. Fluorescence was accumu- 
lated on a four-decade log scale. 
CD80 eDNA Cloning and Mutagenesis.  Total RNA was isolated 
from the Raji cell line using RNAzol (Cinna/Biotecx Laborato- 
ries,  Friendswood,  TX)  and huCD80  cDNA  was  obtained by 
reverse-transcription  PCR (19). The first-strand cDNA was reverse 
transcribed using the CD80-specific antisense  primer. The oligo- 
nucleotides  (forward:  5' CCTAAGCATCTCGAGCCATC,  GC~C- 
ACACAC  3'  and reverse:  5' GCTTCTGCGGATCCTGTTATA- 
CAGGGCGTACAC 3', containing XhoI and BamHI restriction 
sites, respectively) were designed to amplify the entire coding se- 
quence (nucleotides 316-1,187) (8). PCR products were subcloned 
in pBluescriptlI SK- vector and sequenced,  using double-strand 
plasmid as template (20), before subdoning into the eukaryotic ex- 
pression vector pCDLSRcx (21). Site-directed  mutagenesis of the 
human cDNA was performed using the PCK overlap extension 
technique (22).  Briefly, 50 ng of pCDLSKoe-CDS0 plasmid,  50 
pmol of oligonucleotide primers containing the mutations at the 
positions listed in Table 1, and the 5' or 3' oligonucleotide primers 
used previously to done the CDS0 cDNA were used to generate 
two PCR fragments with complementary ends that contain the 
mutated codons. DNA fragments were excised from low melting- 
temperature agarose gel after electrophoresis of the PCK products. 
Overlap extension was  carried out in low melting-temperature 
agarose  using one tenth of each fragment and only the 5' or 3' 
primer to generate a full-length fragment. Depending on the posi- 
tion of the mutations, a 300-bp XhoI-EcoRV or 580-bp EcoRV- 
BamHI digestion fragment was subcloned in the pCDLSR~-CD80 
plasmid from which the corresponding fragment was removed by 
digestion with the appropriate restriction enzymes. Oligonucleo- 
tides  linking the sequence  corresponding to the CD80 residues 
137-142 to that sequence corresponding to residues 240-245 were 
used in a similar two-step PCR procedure to generate the deletion 
mutant AC. The 283-bp EcoRV-BamHI digestion fragment was 
subcloned as described for the other mutants. All PCR-generated 
cDNA and ligation products were entirely sequenced. 
Cell-Cell Adhesion Assay.  CD80-transfected L ceils (and un- 
transfected as negative control) were seeded in triplicate in flat- 
bottom 96-well microtiter plates at 5.104 calls per well the day be- 
fore the assay. The next day, CD28 + Jurkat  T  lymphoma cells 
were loaded with calcein-AM (CAM) in Dulbecco's PBS containing 
0.1% BSA by passive diffusion across viable cells membrane for 
1 h, washed three times with PBS, and added to the plates at 4.10  s 
cells per well. After 30 min incubation at room temperature, nonad- 
herent Jurkat cells were removed by repeated washes with ice-cold 
Ca  2+,  Mg2+-free PBS. The remaining  cells were lysed  in  2% 
Triton X-100 and fluorescence was determined at 485-538 nm using 
a Labsystems Fluorskan II (Flow Laboratories Inc., McLean, VA) 
or Cytofluor 2300 System (Millipore Corp., Bedford, MA) plate 
readers. For each sample, the percentage of  Jurkat cells binding was 
calculated as follows: percentage of binding =  [amount of fluores- 
cence/amount of fluorescence  without washing (total input)]  x 
100. In  mAb-inhibition  experiments, muCDS0  mAb  16-10A1, 
huCD80 mAb L307, huCD28 mAb L293, and their respective con- 
trois were added to the wells at 10 #g/ml 10 min before the addi- 
tion of CAM-loaded Jurkat cells. 
Functional Assay.  Untransfected and transfected L ceils were 
used as costimulators of PHA-activated Jurkat cells. Each assay was 
performed in triplicate as follows: 5  x  104 Jurkat cells were cocul- 
tured with 2,500-104  L cells in the presence  of I  #g/ml PHA. 
This concentration had no effect on the subsequent CTLL prolif- 
eration assay used to determine II-,2 production (data not shown). 
After 20 h, supernatants were collected. In mAb inhibition experi- 
ments, cocultures were performed as described above in the pres- 
ence of the indicated antibodies at 2 or 6 #g/ml. Ib2 production 
was measured using the IL-2-dependent CTLb2 line. Briefly, serial 
twofold dilutions of the cocttlture supernatants  were added to 4,000 
Ib2-dependent CTLL,2 cells. These cttltures were pulsed with I #Ci 
[3H]thymidine for 6 h, 42 h after initiation of the culture. Radio- 
activity was  quantified  on  a  B  counter  (Betaplate;  Pharmacia 
LKB, Uppsala, Sweden) and counts per minute were converted to 
Ib2  units  using  a  standard  curve of recombinant  human  Ib2 
(Cetus Corp.). 
CTLA4-Ig Binding Assay.  For each  transfectant,  2.105 cells 
were incubated with serial dilutions of CTLA4-Ig (6) in PBS con- 
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incubated subsequently with a saturating concentration of FITC- 
conjugated goat anti-human IgG mAb (Fc specific)  (Caltag Labora- 
tories, San Francisco, CA) for an other 30 min on ice. After washing, 
the cells were analyzed on a FACScan  |  as described for flow cytom- 
etry analysis. 
Results 
Generation and Expression of CD80 Mutants.  To study the 
molecular basis of the interaction of CD80 with its counter- 
receptors CD28 and CTLA4, a panel of 24 CD80 mutants 
were generated by PCR and stably transfected into mouse 
L calls. The design of the mutants was initially guided by 
the alignment of the human CDS0 amino acid sequence with 
its routine homologne (Fig. 1) and by the general structural 
properties of Ig-like domains (i.e., residues conserved through- 
out the IgSF that are important to the Ig fold, such as the 
cysteines in the B and F strands, the tryptophane in the C 
strand, or the hydrophobic residues two positions ahead of 
the cysteines,  as well as conserved patterns characteristic of 
the V  or C1 set were not substituted)  (23).  Thus, for ex- 
ample, in the V domain, two stretches of amino acids (63-68 
and 84-91)  are identical in mouse and huCD80.  The first 
stretch (residues 63-68) contains structural features present 
in all V-like domains and was therefore not chosen as a target 
for mutagenesis. The second stretch (positions 84-91) con- 
tains residues that diverge among V-like domains, and it was 
considered-as a more likely candidate for mutagenesis. The 
choice of the residues to be substituted was targeted to the 
regions of the V- and C-like domains predicted to be exposed 
based on the structure of related molecules. Since additional 
ligands for CD28  and  CTLA4  (hu-  and muCD86)  were 
characterized at the molecular level during the process of this 
study, this information was integrated into the design of ad- 
ditional mutants. When all sequences are aligned, it appears 
that among the consensus residues, most of them are critical 
to the Ig fold and are less likely to contribute directly to the 
interaction with CD28 or CTLA4 (Fig.  1 a). The positions 
and natures of these mutations are listed in Table 1. Biochemical 
analysis has shown that both mu- and huCD80 are heavily 
glycosylated molecules. Mutants were also designed to re- 
move seven out of eight potential glycosylation sites of the 
CD80 molecule (M7, M8, M10, M13, M16, and M20-M23). 
The expression and conformational integrity of CD80 mu- 
tants in transfected L cells were first examined by flow cytom- 
etry using four mAbs to huCDS0. All but five mutants showed 
good binding to each of the mAbs (Table 1), indicating that 
the overall structure of the CD80 molecule was not altered 
by the different substitutions.  The most interesting excep- 
tion was M2 (M77A, D80A) in the CDR2-1ike region, which 
completely abrogated BB1 binding while partially affecting 
the binding of mAb 104. This result suggests that the epi- 
a  V-like  domain 
35 
huCD  80  V.  IHVT... K  EVK.. EVATL 
mu  CD 80  -  DEQL... S-  S -  -..  DKVL- 
VL  IVMTQSPSSL  SVSPG  RVTI 
b  b  b 
VH  -QLQESG. GG  LVKPGGSLK- 
*  73 
SCGHNVSVEE  LAQTRIYWQK  .....  EKKMV 
P-RY-SPH-D  ESED ......  .  ....  HD  V 
--RASQNG  ....  SSYLA-YQ  QKPGQSP-LL 
b  b  bbbb  b  b 
--KASGFTFT  ..SYYMH-VR  QRPGKGLEWI 
4-  ...... CDRI  ...... -~ 
huCD80  LTMMS..GDM  NIWPEYKNRT 
muCD80  -SVIA..-KL  KV  ........ 
VL  TY .....  -AS  -LASGVPD-F 
VH  GYINPGN  ST  -YNEKFKG-F 
<--  ...... CDR2  ......  --~ 
huCD80  LKYEKDAFKRE  RLAEVTLSVK 
muCD80  Q-K-RGTYEVK  ---L-K--I- 
VL  WSSSP ....  LT  FCCCTK-EI- 
bb  b  b 
VII  DY-YGS..FDY  WGQGT-VT-S 
CDR3 .....  --~ 
*  118 
IFD...ITNN  LSIVILALRP  SDEGTYECVV 
LY-...N  .T  Y-LI--C-VL  --R  S 
SGSG..SGTD  FTLT-SSVEA  E-LAT-Y-QQ 
TITRDKSSST  AYLQLSSLTS  E-TAV-Y-AR 
139 
b  C-llke  domain 
huCDS0  ADFPTPSISD 
muCD80  ---S--N-TE 
huCDS0  SQDPETELYA 
muCD80  .....  S---T 
*  189 
FEIPTSNIRR  IICSTSGGFP  EPHLSWLFAWC  EELNAIINTTV 
SGN-SADTK-  -T-FA  .....  K-RF  ......  R--PG ....  I 
*  *  *  *  241 
VSSKLDFNMT  TN]KSFMCL/K  YGHLRVNQTF  NWNTTKQEHF  PD 
I--Q  ....  T-  R--TIK ......  DAH-SED  T  EKPPEDP.  -- 
Figure  1.  Comparison of human and murine CD80 
extracelhlar amino acid sequences. The (a) V-like and 
(b) C-like domains are, respectively, 46 and 55% iden- 
tical. The numbering is that of the human CDS0 se- 
quence starting with the first methionine as 1. Residues 
conserved in four out of five B7 family members appear 
in boldface in the human CDS0 sequence while con- 
sensus residues for IgSF members are in italics. Dashes 
in  the other sequences  indicate  residues  identical  to 
human CDS0. Predicted N-linked glycosyhtion sites are 
marked with asterisks. (a) An alignment of the V-like 
human and mouse CDS0 sequences with consensus vari- 
able domains from Ig light and heavy chains. Because 
the alignment between the CDS0 sequences and Ig se- 
quences is low (<30% identity),  the alignment was per- 
formed manually. Special emphasis was given to aligning 
those residues that are hydrophobic  in the CDS0 se- 
quences and those that are buried in known Ig struc- 
tures. Those residues whose side chains have an average 
of >80% of their surface buried in both Ig domains are 
indicated by the letter b.  The locations  of the CDRs 
in the Ig domains  are indicated. 
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MUTATIONS  REGION  mAb STAINING 
1.307  2DI0  104  B81 
V-llke domain 
M1  VEE (56-58) AQQ  CDR1  +++  +++  +++  +++ 
M2  MS~.D (77-80) ASGN  CDR2  ++§  +++  ++ 
M3  W84A  C" -  D  loop  ++§  +++  +++  +++ 
M4  W84 F  C" -  D  loop  +++  +++  +++  +§ 
M5  E86A  C" -  D  loop  +++  +++  +++  +++ 
M6  YB7A  C" -  D  loop  +++  +++  +++  +++ 
M7  Y.KN  (87-89) FKQ  C" -  D  loop  +++  +++  +++  +++ 
Iv18  ~  (87-89)FAQ  C" -  D  loop  +++  +++  +++  +++ 
M9  K88A  C"  -  D  loop  +++  +++  +++  +++ 
M10  N89A  C" -  D  loop  +++  +++  +++  +++ 
MI  I  ~91A  C" -  D  loop  ++++  +++  ++++  +++ 
M12  DII  (94-96)NIA  D -  E loop  ++++  +++  ++++  ++++ 
M13  N98Q  D- E loop  +++  +++  +++  +++ 
M14  IGflEKDA (120-125)  RFSGST  CDR3  +++  +++  +++  +++ 
M15  H 130A  G  strand  +++  ++  +++  +++ 
C-like domain 
Delta  C  deletion (P t43-F 239)  whole  domain 
M16  N  186Q  D strand  ++  ++  +++  +++ 
M17  ,~D  (190-192) AAN  D  -  E loop  +++  +++  +++  +++ 
M18  I~  (194-196] AAQ  D  -  E loop  +  +  +  + 
M19  H 130A,~ 198H  D -  E loop  -/+  -/+  -/+  -/+ 
Iv120  N 207Q  E -  F loop  +++  +++  +++  ++ 
M21  N 207  Q,T  228  A  E -  F loop & G  strand  +++  +++  +++  +++ 
M22  N 207 Q,N 226A  E -  F loop &  G  strand  ++  ++  +++  +++ 
M23  N211  Q  E -  F loop  +++  ++  +++  +++ 
The huCD80  mutants are described,  using the one-letter code,  by the wild-type sequence followed by the 
position  and  the amino  acid  substitution.  Residues  conserved  in muCD80  and huB70 appear  in boldface 
and underlined, respectively,  mAb binding was analyzed by flow cytometry.  For each CD80 mutant, stain- 
ing was  scored  as  relative means  of fluorescence compared  to  wild-type  staining with  the  same  antibody 
at  saturating  concentrations  as  follows:  -,  no  staining  above background;  +  +  +  +,  >200%;  +  +  +, 
50-200%;  +  +,  25-50%;  +,  5-25%;  -/+,  <5%. 
tope for BB1 includes the CDR2-1ike region.  Mutants M18 
and M19 showed poor binding to all mAbs tested, indicating 
a lower level of expression compared to wild-type CDS0. The 
C-like domain  deletion  mutant  (tiC)  was not  detected by 
any of the mAbs,  suggesting  that  it  was  not  expressed at 
the cell  surface. 
Assessment  of the  CD28  Binding  Capacity  of CD80  Mu- 
tants.  The effect of the mutations on binding to CD28 was 
measured by adhesion of CD28 + CTLA4-  human  T  lym- 
Figure  2.  Adhesion interaction of CD80  mutants with huCD28.  (a) 
Binding of CD28 § Jurkat cells to huCD80-transfected L cells is specific 
for  CDS0-CD28  interaction.  Binding  of  CD28 §  cells  to  wild-type 
CDS0 +  cells was  measured in the presence and absence of mAbs at  10 
#g/ml final. The results were normalized, after correction for binding to 
untransfected L  cells,  for the percentage of binding obtained in the ab- 
sence of mAb in each experiment. Percentage of response  =  (percentage 
of binding in the presence of mAb  -  percentage of binding to untrans- 
fected cells)/(percentage of binding in the absence ofmAb  -  percentage 
of binding to untransfected cells)  ￿  100.  (b) Binding of CD28 + Jurkat 
cells to huCDS0  mutants.  The mean  _+  SD  of two  to six independent 
experiments are reported.  To pool the results, binding of Jurkat cells to 
CD80-transfected L cells was corrected for binding to untransfected cells. 
The results were then normalized for the percentage of binding obtained 
with the wild-type in each experiment as follows: Percentage of wild-type 
response =  (percentage of mutant binding  -  percentage ofuntransfected 
binding)/(percentage of wild-type binding -  percentage ofuntransfected 
binding)  ￿  100.  For M2,  M3,  M6,  M18,  and M22,  n  =  6,  10,  4,  4, 
and 5, respectively, wherein n represents the number of independent ex- 
periments. 
670  The  Functional  Region  of CD80/B7-1 phoma Jurkat cells. Since the CD80-CD28 interaction is in- 
dependent  of divalent  cations  (24),  Ca  2+,  Mg2+-free  PBS 
was used in  the final  washing  steps  to minimize  potential 
interference  mediated  by integrins.  Adhesion  to wild-type 
huCD80  was  blocked  by  mAbs  to  huCD28  (L293)  and 
huCDS0 (L307), while mAbs to muCD80 (16-10A1) or other 
control mAbs had no effect (Fig.  2 a). Only three of the mu- 
tations  (M3,  M6, and M18) significantly reduced adhesion 
to CD28 § calls.  Two independent  point mutations  W84A 
(M3) and Y87A (M6) completely abrogated CD28-CD80- 
mediated cell-cell adhesion (Fig.  2  b). These residues lie in 
the region of the first domain corresponding to the C" strand 
and the C'-D  loop of the Ig V  domain  (see  Fig.  5).  The 
more conservative substitutions W84F (M4) and Y87F (M8), 
at either of these residues, retained binding to huCD28.  In 
the C domain, M18 also decreased CD28-mediated cell adhe- 
sion;  however, the comparable reduction in binding for all 
CD80  mAbs (Table  1) indicated  a poor  surface expression 
of this mutant that would account for the low CD28 binding 
to L cells transfected with the mutant.  Mutant M2, which 
ablates binding of mAb BB1, retained CD28-dependent adhe- 
sion, although only at ,'~40% of the wild-type CD80. These 
results, coupled with the ability of BB1 to block stimulation 
of CD28 +  T  cells  by human  CD80-transfected  fibroblast 
(reference 24, and data not shown),  suggest dose, possibly 
overlapping,  but distinct binding  sites for CD28 and BB1- 
antibody on  CD80. 
Oligosaccharides  contribute  significant  mass  to  CD80 
(16-24 kD) as also found in several other IgSF members. To 
examine their possible role in the intermolecular binding to 
CD28, mutations were introduced at seven of the eight sites 
of predicted N-linked glycosylation. As shown in Fig. 2 b, 
among  the  eight  mutants  that  modify putative  N-linked 
glycosylation sites of CD80, M22, which eliminates two sites 
(N207Q and N226A), consistently resulted in a twofold in- 
crease in CD28 binding without affecting cell surface expres- 
sion. Thus, carbohydrates may play some role in the recogni- 
tion  of CD28. 
Mutations in the V Domain of CD80 also Impair the Upregu- 
lation of  lL-2 Production by PHA-stimulatedJurkat Cells,  Con- 
cordant results were obtained in a functional assay for costimu- 
lation.  IL-2 production  is triggered  in Jurkat T  cells using 
a combination of PHA and CD28 mAbs, where PHA substi- 
tutes for TCR mediated signals (25).  Coculturing of CD28 + 
Jurkat  cells  with  CD80-transfected  L  cells  in  the presence 
of a suboptimal concentration of PHA also led to a 6-10-fold 
enhanced secretion of IL-2, compared to similar cultures with 
untransfected cells (Fig.  3 a). This enhancement  was depen- 
dent on huCD80, since it was completely inhibited by mAb 
L307, while isotype controls and mAb 16-10A1  to muCD80 
had no effect (Fig.  3 a).  This functional  assay was used to 
analyze the  interaction  of CD28  with  the panel  of CD80 
mutants. Each mutant was tested two to six times. The results 
of a representative experiment are shown in Fig. 3 b. Consis- 
tent  with  the results  of the adhesion  assay, only M3,  M6, 
and M18 significantly reduced the IL-2 response to near back- 
ground levels  (Fig.  3  b).  The reduced IL-2 production  ob- 
served with  M18 likely reflects its  poor expression. 
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Figure 3.  Functional  assay  of the CD28-CD80 interaction. (a) CD80- 
transfected L cells costimulate Ib2 production by PHA-activated  Jurkat 
calls in a CD28-CD80-dependent manner. 104 L cells stably  transfected 
with CD80 (or untransfected Lmtk- cells as control) were  cocultured  for 
20 h with 5.104 PHA-activated  Jurkat cells, as described  in Materials and 
Methods, in the presence  of the indicated antibodies at 2 or 6/~g/ml. Su- 
pernatants were then assayed  for IL-2. The means _+ of triplicate samples 
of one out of three representative experiments are shown. (b) Functional 
capacity  of CD80 mutants. L cells transfected  or not with different forms 
of CD80  were  cocultured  with PHA-activated  Jurkat cells  at a stimulator/re- 
sponder ratio of 1:20 (hatched  bars)  and 1:5 (dotted  bars). Ib2 production 
is indicated as the mean _+ SD triplicate samples. Each individual mutant 
has been tested from 2 to 10 times. One out of six representative experi- 
ments is shown. 
Mutations  of CD80 Abrogating  CD28 Binding  also Affect 
CTLA4 Binding.  Linsley et al. have shown that a chimeric 
form of CTLA4-Ig,  CTLA-Ig,  binds CD80 with a 10-20- 
fold higher affafity than a similar CD28 chimera (6). Moreover, 
CTLA4-Ig competes efficiently with CD28 for binding  to 
CD80. The interaction between CTLA4-Ig and the above- 
described pand of CD80 mutants was analyzed by flow cytom- 
etry using a range of concentrations of CTLA4-Ig spanning 
over three orders  of magnitude.  Binding  of CTLA4-Ig  to 
murine L cells required the expression of the huCD80 mole- 
cule,  and the level of fluorescence was proportional  to the 
amount of CTLA4-Ig added to CD80 + cells. Mutants that 1400 
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Figure 4.  Binding  of CTLA4-Ig to CDS0 mutants. 
L cells  expressing  comparable  levels  of  CDS0  wild type, 
M3, M4, M5, M6, and M9 (and untransfected Lmtk- 
cells as negative  control) were  incubated  with increasing 
amounts of CTLA4-Ig. Bound CTLA-Ig was revealed 
by FITC-labeled  goat anti-human "y chain (Fc specific) 
and cells  were  analyzed  by FACScan|  two independent 
experiments are presented in a and b. Results are ex- 
pressed  as means of  green fluorescence  (in arbitrary  units) 
plotted against the concentration (nanograms per mil- 
liliter) of CTLA4-Ig. 
did not have any effect in the adhesion assay or in the func- 
tional assay were all capable of binding CTLA4-Ig to levels 
comparable to the wild-type molecule (Fig. 4 a and data not 
shown). Mutants M3 and M6, however, reprodudbly showed 
reduced binding to CTLA4-Ig, even at the highest concen- 
trations  (Fig.  4, a  and  b). 
Discussion 
We have identified a functional  region in the V-like do- 
main of human CDS0 by assessing the capacity of CD80 mu- 
tants to retain costimulatory activity. Three different assays 
have implicated residues W84 and Y87, which lie in the se- 
quence WPXYKNRT that is conserved across species (mouse, 
human,  and rat) in CDS0 (8, 9, 26), in the interaction with 
CD28 and CTLA4. The nonconservative substitution of al- 
anine at these positions led to a marked decrease in the inter- 
action with both counterreceptors,  while the more conser- 
vative substitution of phenylalanine  had little effect on the 
same assays. These results suggest that the hydrophobic side 
chain of  residues W84 and Y87 either directly contact CD28 
and CTLA4  or are essential in maintaining  the local con- 
formation of this binding site region.  The finding that key 
determinants of the BB1 epitope (an mAb inhibiting CDS0- 
dependent T  cell responses [3]) lie proximal to the site fur- 
ther argues that this region is involved in recognition of CD28 
and CTLA4.  Based on alignments  of the V-like domain of 
CDS0 with consensus Ig V regions, the WPXYKNRT motif 
is predicted to lie between the CDR2 loop and the D  strand 
(Fig.  5).  If organized as in a typical V domain,  this region 
would include the C"/3 strand of the CDR2 region. Interest- 
ingly, the CDR2-1ike region has already been implicated in 
the interaction between two other members of the IgSF CD2 
and CD58  (LFA-3) (27).  On CD28 and CTLA4,  a hydro- 
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Figure 5.  Model  of  the  /3 
strand  folding  pattern  of  CD80 
V-like  domain. The residues  im- 
plicated  in CD28  and CTLA4 
binding  are  indicated  in  ted and 
are  localized  to  the  C" strand  and 
C" to  D loop.  R~lues implicated 
in  binding  to  mAb BBI appear  in 
yellow. The canonical  disulfide 
bond in  Ig  domains between the 
B  and F strands  is shown as a 
dashed  line.  Because of  the low 
homology  between  CD80  and 
other  V-like  domains,  it  was  neces- 
sary  to  manually  gene~te  an  align- 
ment against  consensus  VH and 
Vt sequences.  The structure  was 
thus  predicted  by  placing  special 
emphasis on the location  of  hy- 
drophobic residues in positions 
that are buffed in analogous Fv 
structures. phobic region in the CDR3, encompassing a MYPPPY motif 
that is conserved among both molecules and across species 
(28), is critical for the interaction with CD80 (reference 29 
and Truneh, A., manuscript in preparation).  Moreover, in- 
teractions  between  proline-rich  motifs  and  hydrophobic 
residues have been involved in binding of Src homology 3 
regions to their targets  (30). Finally, hydrophobic contacts 
have also been observed or suggested for the interaction of 
other IgSF molecules with their protein ligands  (31-34). 
Although the sensitivity of the two assays used to assess 
CD28 and CTLA4 binding capacity of the mutants might 
differ and do not allow direct comparison,  the differential 
read-out that was obtained toward both counterreceptors raises 
the possibility  that additional  residues of CD80 might be 
critical to the interaction with CTLA4. In fact, contrary to 
CD28 binding, which was totally abrogated, even when using 
20-fold excess of responder cells, the alanine substitution at 
residues 84 and 87, retained a low level of  binding to CTLA4- 
Ig. This result indicates that other residues may be involved 
in recognition of CTLA4 and possibly contribute to the higher 
affinity of CD80 for the CTLA4-Ig molecule. This hypoth- 
esis would be consistent with the recent finding that the CDR1 
of CTLA4 was responsible for the difference in affinity to- 
ward CD80 (29) when compared with CD28. CTLA4 could 
thus contact other regions  of CD80 through its  CDR1. 
In the CD80 region we identify here as critical for binding, 
Y87 is conserved among all members of the B7 family, in- 
cluding hu- and muCD86, whereas W84 is not (13). The 
MYPPPY region of CD28 mentioned above appears to be 
also important for binding to the more recently described 
ligand CD86 (B7-2, B70),  indicating that the interactions 
of CD28 with its ligand(s) on B cells probably involve con- 
served residues (Truneh, A., manuscript in preparation). CDS0 
and CD86 bind with similar avidities to both CD28 and 
CTLA4, although the dissociation of CTLA4 from CD86 
occurs faster than from CD80 (35). It will thus be of interest 
to determine whether these residues have a common role in 
recognition of CD28 and CTLA4 by CD86. 
The role of the C  domain of CD80 has been addressed 
in our experiments and in two recent studies (36, 37). Our 
attempt to address this question by deleting the C domain 
did not lead to conclusive results since  this construct was not 
expressed  in repeated transfections. Using an alternative spliced 
form of muCD80 that lacks exon 3 encoding for the CD80 
C domain, two groups  have reported conflicting results as 
to the capacity of the truncated molecule to interact with 
CD28 and CTLA4. Inobe et al. (36) demonstrate that both 
molecules have high affinity interactions with the truncated 
CD80. Interestingly, CTLA4-Ig binding activity was reduced 
by opposition, suggesting that CTLA4 has additional require- 
ments (possibly the C domain) for high affinity binding to 
B7 molecules. In contrast, Guo et al.  (37) show that this 
truncated form of CD80 does not bind CD28 and CTLA4. 
Moreover, mutations at conserved residues within the C do- 
main also fail to bind both CD80 ligands. It is noteworthy, 
however, that four out of the six mutants generated in this 
study involve prolines known to be critical for the structural 
integrity of molecules. These results are difficult to reconcile 
with our own. Indeed,  we have generated mutants in the 
amino acid stretch SDQXXXELY located in the C-like do- 
main and pointed to as of potential importance by Freeman 
et al.  (9). These residues are conserved among CD80 and 
CD86 across species  (8-13, 26). Three mutants of the present 
study were altered in this sequence. M17 had no effect on 
function, while M18 and M19 drastically reduced cell surface 
expression of CD80 as measured with all our panel of mAbs. 
These results suggest that this region of the molecule could 
be involved in other functions of the molecule such as dimer- 
ization  or  interaction with  other cell  surface molecules. 
Moreover, as previously mentioned, antibodies that affect the 
CD80-CD28/CTLA4 interaction map to the V domain. Fur- 
ther studies will be required to determine the role of the C 
domain in recognition of CD28 and CTLA4. Thus, while 
our results provide direct evidence for the involvement of the 
NH2-terminal,  V-like domain of CD80  in its  interaction 
with CD28 and CTLA4, the contribution of the C-like do- 
main can not be ruled out. A more definitive resolution of 
the interactions between CD80/B70 and CD28/CTLA4 may 
await structural analysis. 
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